Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Yкраїнський (UK)
Przejdź do strony domowej biblioteki Centralna Biblioteka Wojskowa Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaCentralna Biblioteka Wojskowa

Wyszukujesz frazę "drugs." wg kryterium: Temat

  Lista filtrów
Wyrównaj
    Wyświetlanie 1-12 z 12
    Tytuł:
    THE COMPREHENSIBILITY OF LEAFLETS ATTACHED TO OTC ANALGESICS – PILOT SURVEY OF OPINIONS IN POLAND
    Autorzy:
    Bułaś, Lucyna
    Hansel, Justyna
    Wajda, Anna
    Dolińska, Barbara
    Drozd, Mariola
    Powiązania:
    https://bibliotekanauki.pl/articles/895603.pdf
    Data publikacji:
    2019-12-29
    Wydawca:
    Polskie Towarzystwo Farmaceutyczne
    Tematy:
    OTC analgesics
    leaflet attached to the drugs
    source of information about OTC drugs
    Opis:
    The aim of the study was to present the opinions on the leaflets attached to the packages of Over-the-counter (OTC) analgesics, taking into account the place of purchase and the usefulness of the information contained in the leaflet. The survey was conducted in Poland at the turn of February/March 2016 and June/July 2017. The authors constructed an original questionnaire consisting of 24 questions, both open and closed type. The survey was addressed to adults. In total 303 respondents were surveyed. Student t-test and Pearson’s chi-squared test were applied to determine differences between statistics, p < 0.05 was assumed as statistically significant. The respondents indicated a pharmacy as the main place of purchasing OTC analgesics. Most of the respondents declared that they read the leaflet attached to the package, and the font size used is large enough and legible. However, if it is difficult to read the information contained in it, and the majority of patients do not turn to the doctor or pharmacist for advice. The obtained results confirm that patients purchase and use drugs with increasing awareness. The study found that patients do not always understand drug information leaflets, and they do not always turn to professionals for counseling. The information contained in leaflets should be presented in a way that is clear, concise, and easily understandable to patients. It appears that the implementation of pharmaceutical care would greatly improve the safety of pharmacotherapy, including OTC non-steroidal anti-inflammatory drugs (NSAIDs).
    Źródło:
    Acta Poloniae Pharmaceutica - Drug Research; 2019, 76, 6; 1099-1106
    0001-6837
    2353-5288
    Pojawia się w:
    Acta Poloniae Pharmaceutica - Drug Research
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Preparation of scutellarin loaded TPGS polymeric micelles and evaluation of its pharmacokinetics and pharmacodynamics effects in rats
    Autorzy:
    Zou, Liu
    Xiong, Shujuan
    Deng, Xiangping
    Liu, Juan
    Xiong, Runde
    Wang, Zhe
    Cao, Xuan
    Chen, Yanming
    Guo, Yu
    Tang, Guotao
    Powiązania:
    https://bibliotekanauki.pl/articles/895637.pdf
    Data publikacji:
    2018-12-31
    Wydawca:
    Polskie Towarzystwo Farmaceutyczne
    Tematy:
    scutellarin
    TPGS
    polymeric micelles
    antithrombotic drugs
    Opis:
    To improve the clinical effect of scutellarin by extending the action time in vivo, scutellarin loaded polymeric micelles were developed by D-alpha tocopherol polyethylene glycol 1000 succinate (Scu/TPGS). Scu/TPGS were prepared using film solvent diffusion methods and characterized on the basis of their particle size, zeta potential, and drug encapsulation efficiency. Dynamic dialysis was used to study the release behavior of the polymeric micelles in vitro. Its pharmacokinetic characteristics and antithrombotic efficacy were studied by intravenous injection in rats. The results showed that Scu/TPGS were spherical, 20.09±2.62 nm in size and a slow release in vitro. The pharmacokinetic parameter T1/2 of Scu/TPGS was 762.12±46.56 min compared with commercial injection of 59.30±10.67 min (p<0.05). At the 1 mg/kg dose, the thrombolysis effect of micellar group was stronger than that of the commercial group (p<0.05). In conclusion, TPGS polymer micelles provided a valid strategy in chemotherapy for cerebrovascular diseases with poor water solubility and poor lipid solubility drugs such as scutellarin.
    Źródło:
    Acta Poloniae Pharmaceutica - Drug Research; 2018, 75, 6; 1305-1312
    0001-6837
    2353-5288
    Pojawia się w:
    Acta Poloniae Pharmaceutica - Drug Research
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    FACTORS ASSOCIATED WITH ESTIMATE OF HIGH TERATOGENIC RISK IN FEMALES EXPOSED TO ANTI-INFECTIVE AND ANTI-INFLAMMATORY DRUGS DURING PREGNANCY
    Autorzy:
    Grubor, Iva
    Nikolić, Ljiljana
    Ružić Zečević, Dejana
    Milovanović, Dragan
    Folić, Marko
    Rosić, Nikola
    Radonjić, Vesela
    Janković, Slobodan M.
    Powiązania:
    https://bibliotekanauki.pl/articles/895244.pdf
    Data publikacji:
    2018-12-31
    Wydawca:
    Polskie Towarzystwo Farmaceutyczne
    Tematy:
    pregnancy
    drugs
    risk of teratogenicity
    risk estimate
    Opis:
    ABSTRACT Introduction. Considering that small number of drugs are completely safe for use during pregnancy, right choice and adequate risk assessment is extremely important. Objective. The aim of this study was to analyze factors associated with estimate of high teratogenic risk (as judged by clinical pharmacologist) in pregnant females who were prescribed anti-infective drugs or mild analgesics. Methods. A cross-sectional study included 284 pregnant women who came for an advice about teratogenic risk to clinical pharmacologist in Clinical Centre Kragujevac, Serbia during the period from 1997 to 2012. All of included pregnant women were prescribed mild analgesics and/or anti-infective drugs during the first 3 months of pregnancy. The data were collected from patient files and by phone interviews. Results. Clinical pharmacologists estimated the risk of teratogenicity as “high” in pregnant females who were using tetracyclines or propionic acid derivatives. Disorders of development reported by mothers during phone interviews were associated with cephalosporin use during first 3 months of pregnancy, while miscarriages or abortions happened more often in women who used a tetracycline. Conclusions. Estimate of risk from congenital anomalies after use of drugs during pregnancy, which make clinical pharmacologists as part of their routine healthcare services, depends on amount of published data about previous experiences with specific drugs during the first 3 months of pregnancy. Key Words: pregnancy; drugs; risk of teratogenicity; risk estimate
    Źródło:
    Acta Poloniae Pharmaceutica - Drug Research; 2018, 75, 6; 1439-1445
    0001-6837
    2353-5288
    Pojawia się w:
    Acta Poloniae Pharmaceutica - Drug Research
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Poles in pharmacy - source of knowledge and prevalence of over the counter usage
    Autorzy:
    Bandurska, Ewa
    Zaleska, Judyta
    Zarzeczna-Baran, Marzena
    Powiązania:
    https://bibliotekanauki.pl/articles/895595.pdf
    Data publikacji:
    2018-08-31
    Wydawca:
    Polskie Towarzystwo Farmaceutyczne
    Tematy:
    respiratory tract infections
    Self Care
    Nonprescription Drugs
    Opis:
    Self-medication is a procedure that is increasingly eagerly chosen by people all over the world, especially in common conditions (e.g. infections of upper respiratory tract). The main objective of this study was to determine the prevalence of self-medication and identify the sources of knowledge used by Polish society in searching for information on OTC medicines. The study was conducted in the group of 252 Internet users at working age (18-64 years) living in Poland (women n=208; 82.5%, men m=44; 17.5%) and used an original questionnaire consisting of 29 questions available on Internet from December 2016 to February 2017. According to the obtained results self-treatment was undertaken by 90.08% of Poles. Using OTC products was most prevalent among people with university education (p=0.01) and without children (p=0.03). Most popular source of knowledge on self-medication was own experience (n=149; 59.1%) and pharmacists’ advice (n=148; 58.7%). TV commercials were considered as unimportant for most of respondents (54.3%). Young women (18-26 years) most often used Internet to search for information about OTC drugs (p=0.03), young male trusted own experience (p=0.03) and men from older age groups (p=0.04) advice of a pharmacist. Self-medication can characterized as prevalent in Poland. People with lower levels of education used OTC medicines less often and therefore might benefit from stronger support of professionals.
    Źródło:
    Acta Poloniae Pharmaceutica - Drug Research; 2018, 75, 4; 1041-1049
    0001-6837
    2353-5288
    Pojawia się w:
    Acta Poloniae Pharmaceutica - Drug Research
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    APPLICABILITY OF THE EVIDEM MULTI-CRITERIA DECISION ANALYSIS FRAMEWORK FOR ORPHAN DRUGS – RESULTS FROM A STUDY IN 7 EURASIAN COUNTRIES.
    Autorzy:
    Baran-Kooiker, Aleksandra
    ATIKELER, Kagan
    GAITOVA, KAMILLA
    HOLOWNIA-VOLOSKOVA, MALWINA
    TURCU-STIOLICA, ADINA
    Kooiker, Coen
    PINIAZHKO, ORESTA
    CZECH, MARCIN
    Powiązania:
    https://bibliotekanauki.pl/articles/895230.pdf
    Data publikacji:
    2019-06-28
    Wydawca:
    Polskie Towarzystwo Farmaceutyczne
    Tematy:
    rare diseases
    MCDA
    orphan drugs
    EVIDEM
    HTA
    weighting
    Opis:
    Several Multi-Criteria Decision Analysis (MCDA) models for use in health technology assessment (HTA) have been developed over the years, including some for orphan drugs (OD). However, there is no general consensus yet on MCDA structure and which criteria should be included and implementation of MCDA into HTA practice has been slow so far. Our study tested the criteria preferences and possibilities for implementation of the EVIDEM MCDA framework for OD with a diverse group of 140 stakeholders in Kazakhstan, Netherlands, Poland, Romania, Russia, Turkey and Ukraine (KZ,NL,PL,RO,RU,TR,UA). The research elicited stakeholder preferences (weighting) for EVIDEM domains, criteria and sub-criteria to measure their relative importance. Correlations of work place and HTA/rare diseases experience with weighting results were investigated. Results showed that the ‘Need for intervention’ domain was assessed as the most important in: RO/NL/RU/TR, in KZ/PL the ‘Type of benefit of intervention’ and in UA ‘Economic consequences of intervention’. ‘Population Priorities’ was uniformly given a low priority. Further research, sharing of experiences and multi-stakeholder discussion is necessary to define a path forward for a robust and sustainable improvement of MCDA models and its application in orphan drug HTA. Model simplification and clarification of outcomes would be beneficial.
    Źródło:
    Acta Poloniae Pharmaceutica - Drug Research; 2019, 76, 3; 581-598
    0001-6837
    2353-5288
    Pojawia się w:
    Acta Poloniae Pharmaceutica - Drug Research
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    THE INFLUENCE OF POLYETHER SUBSTITUENTS ON BIOLOGICAL ACTIVITY OF CURCUMIN DERIVATIVES
    Autorzy:
    Gruber, Beata M.
    Tomasz, Deptuła
    Adam, Krówczyński
    Irena, Bubko
    Powiązania:
    https://bibliotekanauki.pl/articles/895397.pdf
    Data publikacji:
    2020-02-29
    Wydawca:
    Polskie Towarzystwo Farmaceutyczne
    Tematy:
    Chemical synthesis
    cytotoxic activity
    curcumin derivatives
    antitumor drugs
    Opis:
    Curcumin is reported as an anti proliferative and chemopreventive compound. However, it shows poor water solubility, low bioavailability, and rapid metabolism.. To address these problems, curcumin derivatives substituted with polyether chain were synthesised to improve the hydrophilicity of curcumin and thus its bioavailability. The biological activity of modified curcumin molecules were studied with human normal B-lymphocytes GM 14667 and human leukemia cells HL60 and covered: the denotation of IC50 values for each new compound with use of MTT test and the studies on apoptosis induction observed as morphological changes and the expression of apoptotic proteins, BAX, BCL-2 and survivin with use of Western Blot analysis. All effects were referenced to native curcumin. The derivatives with modified polyether chains number and the position of methoxy- groups were selected for further studies. As was shown, the solubility of the compound does not directly correlate with its cytotoxicity. The maintenance of the methoxy group in the meta position as well as the introduction of hydrophilic polyether chains but not the number of polyether chains may affect the cytotoxic activity of curcumin derivatives against cancer cells. Modifications of the curcumin molecule structure can determine its impact on the profile of pro or anti apoptotic proteins.
    Źródło:
    Acta Poloniae Pharmaceutica - Drug Research; 2020, 77, 1; 99-111
    0001-6837
    2353-5288
    Pojawia się w:
    Acta Poloniae Pharmaceutica - Drug Research
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    OVERVIEW OF REGULATORY INITIATIVES IN THE EUROPEAN UNION TO STIMULATE RESEARCH AND ACCELERATE ACCESS TO ORPHAN DRUGS AND OTHER HIGH MEDICAL NEED PRODUCTS
    Autorzy:
    Baran-Kooiker, Aleksandra
    Czech, Marcin
    Kooiker, Coen
    Powiązania:
    https://bibliotekanauki.pl/articles/895541.pdf
    Data publikacji:
    2019-02-28
    Wydawca:
    Polskie Towarzystwo Farmaceutyczne
    Tematy:
    orphan drugs
    regulatory pathways
    PRIME
    MAPPs
    FP7
    Opis:
    The European Union (EU) is continuously working towards further promoting and facilitating registration and development of OMPs. The goal of this article is to present a broad overview of existing legislation, programmes and incentives in the EU that allow for accelerated access of orphan drugs and high medical need products, as well as give some historical context and how these programs are interconnected. The authors conducted an explorative review of publicly available sources of regulatory intelligence policy and information on orphan drug and rare disease policies as well as information on accelerated assessment programs in the EU. The authors identified and looked into the following programs and initiatives: orphan drug legislation, accelerated assessment, conditional approval, Priority Medicine (PRIME), compassionate use programs, off-label use and RTU, Medicines Adaptive Pathways to Patients (MAPPs), ADAPT-SMART, HTA initiatives (EUnetHTA, Parallel Consultation), STAMP, IMI and IMI2 and the European Framework Programmes (incl. FP7 IDEAL, Asterix and Inspire). It can be concluded that promoting innovation and early access to medicines has been firmly put on the agenda in the EU, with various programs and initiatives, either national or EU-wide. Hurdles in regulatory science remain present, especially for rare diseases, but fundamental research as done in FP7 could lead to more efficient orphan drug development. Barriers in the field of HTA, pricing and reimbursement still need to be addressed to enhance patient access. The true effectiveness of all these programs will only become clear over time.
    Źródło:
    Acta Poloniae Pharmaceutica - Drug Research; 2019, 76, 1; 3-17
    0001-6837
    2353-5288
    Pojawia się w:
    Acta Poloniae Pharmaceutica - Drug Research
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    COMBINATIONS OF ISOTHIOCYANATES WITH DRUGS – A CHANCE OR THREAT TO CHEMOPREVENTION AND CANCER TREATMENT?
    Autorzy:
    Mielczarek, Lidia
    Chilmonczyk, Zdzisław
    Suchocki, Piotr
    Wroczyński, Piotr
    Wiktorska, Katarzyna
    Powiązania:
    https://bibliotekanauki.pl/articles/895549.pdf
    Data publikacji:
    2018-08-31
    Wydawca:
    Polskie Towarzystwo Farmaceutyczne
    Tematy:
    chemotherapy
    chemoprevention
    combination therapy
    sulforaphane
    isothiocyanates
    drugs combination
    Opis:
    Isothiocyanates (ITCs) are a group of compounds of natural origin which exhibit anticancer properties. In addition to the cytotoxic impact on cancer cells, confirmed in the multiple cell lines and the in vivo models, ITCs exhibit the cytoprotective effect in normal cells by regulating the activity of enzymes involved in xenobiotic metabolism. These properties of ITCs have led to a continuing increase in the number of studies which have shown that ITCs can sensitize cancer cells to cytostatic drugs used as standard in cancer therapies. On the other hand these compounds may decrease the effectiveness of drugs by deregulating the metabolising system of the cell. This paper discusses the results of preclinical study on ITCs applications in combination therapy as well as their role in drug metabolism.
    Źródło:
    Acta Poloniae Pharmaceutica - Drug Research; 2018, 75, 4; 829-841
    0001-6837
    2353-5288
    Pojawia się w:
    Acta Poloniae Pharmaceutica - Drug Research
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Scoring ligand efficiency
    Autorzy:
    Polanski, Jaroslaw
    Duszkiewicz, Roksana
    Pedrys, Anna
    Gasteiger, Johann
    Powiązania:
    https://bibliotekanauki.pl/articles/895599.pdf
    Data publikacji:
    2019-08-30
    Wydawca:
    Polskie Towarzystwo Farmaceutyczne
    Tematy:
    drugs
    activity
    drug design
    ligand efficiency
    PubChem
    ChEMBL
    Opis:
    Ligand efficiency (LE) is a molecular descriptor that probes the ratio of potency vs. heavy atom count (HAC). As an estimator of drug candidates, LE emphasizes a low heavy atom count more than potency. The objective was to design a novel transform where potency and the HAC would be balanced more evenly. A series of novel descriptors SCORE was defined to evaluate the co-influence of potency and the HAC. In particular, the product ligand efficiency (PLE) was designed and tested using the data of the ChEMBL, PubChem as well as the selected series of drugs and drug-fragments.
    Źródło:
    Acta Poloniae Pharmaceutica - Drug Research; 2019, 76, 4; 761-768
    0001-6837
    2353-5288
    Pojawia się w:
    Acta Poloniae Pharmaceutica - Drug Research
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    ADVANCES AND LIMITATIONS IN PHARMACOTHERAPY OF EPILEPSY
    Autorzy:
    Rapacz, Anna
    Powiązania:
    https://bibliotekanauki.pl/articles/895429.pdf
    Data publikacji:
    2018-10-31
    Wydawca:
    Polskie Towarzystwo Farmaceutyczne
    Tematy:
    suicide
    epilepsy
    third-generation anticonvulsant drugs
    drug development
    pharmacoresistance
    Opis:
    Epilepsy is a chronic neurologic disorder that affects about 0.7% of the population. Patients with epilepsy suffer from recurrent seizures, which can be focal or generalized in nature. The third-generation of anticonvulsant drugs includes lacosamide, rufinamide, vigabatrin, retigabine, perampanel, eslicarbazepine acetate, brivaracetam and stiripentol. Other compounds, such as ganaxolone, cannabidiol, selurampanel, and everolimus among others, with different mechanisms of action are currently in clinical development. Furthermore, numerous compounds or classes of compounds are investigated in preclinical studies. Nevertheless, about 30% of epilepsy patients suffer from uncontrolled seizures despite pharmacotherapy, including the third-generation of anticonvulsant drugs. Additionally, the occurrence of adverse drug effects is responsible for poor compliance as well as discontinuation of the therapy, in up to 25% of patients before having reached the effective dose amount. Neuropsychiatric undesirable effects, include depression, aggression, irritable mood, anxiety, mood instability, paranoid ideation, delusions, hallucinations. Moreover, suicidal ideation and behaviour have been reported in patients treated with anticonvulsant drugs.
    Źródło:
    Acta Poloniae Pharmaceutica - Drug Research; 2018, 75, 5; 1069-1082
    0001-6837
    2353-5288
    Pojawia się w:
    Acta Poloniae Pharmaceutica - Drug Research
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    THE EFFECT OF METRONIDAZOLE ON THE VIABILITY OF CAL-27 TONGUE CANCER CELLS.
    Autorzy:
    Tołoczko-Iwaniuk, Natalia
    Dziemiańczyk-Pakieła, Dorota
    Celińska-Janowicz, Katarzyna
    Drągowski, Paweł
    Groth, Dawid
    Reszeć, Joanna
    Car, Halina
    Borys, Jan
    Miltyk, Wojciech
    Powiązania:
    https://bibliotekanauki.pl/articles/895561.pdf
    Data publikacji:
    2018-10-31
    Wydawca:
    Polskie Towarzystwo Farmaceutyczne
    Tematy:
    metronidazole
    oral cancer
    CAL-27
    carcinogenic potential of the drugs
    Opis:
    Metronidazole belongs to the most commonly prescribed medications for bacterial and parasitic infections worldwide. It is also used in perioperative prevention prior to bowel, and head and neck surgeries. Despite the fact that the World Health Organization has placed it on its List of Essential Medicines, it is considered potentially carcinogenic. A great number of research studies have been conducted to clarify this issue, but results are inconclusive. None of the studies focused on the influence of metronidazole on oral cancer development. The aim of our study was to evaluate the impact of metronidazole on the viability of tongue cancer cells. The research was conducted on the tongue squamous cell carcinoma cell line (CAL-27). Metronidazole dissolved in growth medium was applied to the cell culture at concentrations: 1, 10, 50, 100μg/mL. Toxicity of the drug was evaluated by MTT assay and the [3H]-thymidine incorporation test. The MTT test revealed a significant increase in cell viability under the influence of metronidazole after 24h, at the highest concentration of the drug (100μg/mL), but had no impact on cell viability at other concentrations and after 48h and 72h. The results of the [3H]-thymidine incorporation test did not show significant results. Summarizing, metronidazole stimulates the viability of tongue squamous cell carcinoma cells according to its concentration and the time of incubation (results significant at the concentration 100μg/mL, after 24 hours of incubation).
    Źródło:
    Acta Poloniae Pharmaceutica - Drug Research; 2018, 75, 5; 1233-1240
    0001-6837
    2353-5288
    Pojawia się w:
    Acta Poloniae Pharmaceutica - Drug Research
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
    Tytuł:
    Bridging East with West of Europe – a comparison of orphan drugs policies in Poland, Russia and the Netherlands
    Autorzy:
    Baran, Aleksandra
    Czech, Marcin
    Kooiker, Coen
    Hołownia, Malwina
    Sykut- Cegielska, Jolanta
    Powiązania:
    https://bibliotekanauki.pl/articles/895663.pdf
    Data publikacji:
    2018-12-31
    Wydawca:
    Polskie Towarzystwo Farmaceutyczne
    Tematy:
    reimbursement
    rare diseases
    orphan drugs
    disease registries
    national plan for rare diseases
    new born screening
    Opis:
    The goal of this article is to provide an in-depth review of rare disease policies and the reimbursement of ODs in 3 European countries, two EU members (Poland, the Netherlands) and a non-EU one (Russia). A review of publicly available information on rare disorder policies and HTA processes was performed. Experts were consulted for unclear or scarce information. Russia has a five times higher frequency threshold for its rare disease definition than Poland and the Netherlands (both using the EU definition). The Netherlands has vastly increased its disease registries by instituting 300 expert centres via its National Plan, in Poland there are only 6 registries while in Russia one central registry exists. All 3 countries have an HTA process in place, however, the Russian one is relatively undeveloped. The access to ODs in the Netherlands is the broadest with 80 out of 83 EMA approved ODs reimbursed in 2015; Poland reimbursed 49, whereas Russia reimbursed 4 on the federal level and 43 in Moscow region. In all countries new rare disease policies are under development. The availability of healthcare systems solutions and the reimbursement of ODs differs greatly in all 3 countries, mainly in Russia. Even though both states are EU member with common regulations and access to EMA approved drugs, marked differences between Poland and the Netherlands in the range of policies, access to treatments and screening programs exist.
    Źródło:
    Acta Poloniae Pharmaceutica - Drug Research; 2018, 75, 6; 1409-1422
    0001-6837
    2353-5288
    Pojawia się w:
    Acta Poloniae Pharmaceutica - Drug Research
    Dostawca treści:
    Biblioteka Nauki
    Artykuł
      Wyświetlanie 1-12 z 12

      Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies